Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
PaperCitations, authors & open-access status
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,293 citations, 2020 year and bronze oa status.
1,293
Citations
2020
Year
bronze
OA Status